Although most previous studies of KRAS mutations have been conducted in patients with NSCLC, previous studies have reported conflicting results regarding the association between KRAS mutations and the efficacy of immunotherapy [92,93,94]. Here, KRAS is linked to non-small cell lung carcinoma.